AstraZeneca lifts 2024 outlook
AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...
LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...
Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...
AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Senior Independent Non-Executive Director, Philip Broadley, has made a notable ...
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...
Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...
AstraZeneca AZN0.05%increase; green up pointing triangle said it plans to pump $2 billion in new investment into the U.S., ...
London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback